Semisolid Dosage
Semisolid Dosage
English[eng]
dermal drug delivery||diffusion cell||Franz diffusion||Skin-PAMPA||Strat-M® membrane||nanocarrier||nonivamide||methyl cellulose||skin penetration||substantivity||thermogel||tacrolimus formulation||nanogels||drug delivery||human excised skin||Jurkat cells||in situ hydrogel-forming powder||nitric oxide-releasing formulation||S-nitrosoglutathione (GSNO)||antibacterial||wound dressing||wound healing||dermal delivery||porcine skin||in vitro permeation||methadone||pain||in vitro||permeation||niacinamide||solvent||PAMPA||skin||curcumin||deformable liposomes||liposome surface charge||hydrogel||chitosan||wound therapy||IVRT||metronidazole||topical cream||semisolid dosage forms||sameness||FDA’s SUPAC-SS guidance||acceptance criteria||positive and negative controls||discriminatory ability||Amphotericin B||Sepigel 305®||Leishmania infantum||cutaneous leishmaniasis||topical treatment||birch bark extract||oleogels||hydrogen bonding||triterpene||rheology||gel strength||eosinophilic esophagitis||budesonide||xanthan gum||guar gum||mucoadhesion||esophagus permeability||rheological characterization||pediatric medicine||compounded preparation||non-ionic emulsifiers||intercellular lipids||confocal Raman spectroscopy (CRS)||polyethylene glycol alkyl ethers||polyethylene glycol sorbitan fatty acid esters||n/a
English[eng]
dermal drug delivery||diffusion cell||Franz diffusion||Skin-PAMPA||Strat-M® membrane||nanocarrier||nonivamide||methyl cellulose||skin penetration||substantivity||thermogel||tacrolimus formulation||nanogels||drug delivery||human excised skin||Jurkat cells||in situ hydrogel-forming powder||nitric oxide-releasing formulation||S-nitrosoglutathione (GSNO)||antibacterial||wound dressing||wound healing||dermal delivery||porcine skin||in vitro permeation||methadone||pain||in vitro||permeation||niacinamide||solvent||PAMPA||skin||curcumin||deformable liposomes||liposome surface charge||hydrogel||chitosan||wound therapy||IVRT||metronidazole||topical cream||semisolid dosage forms||sameness||FDA’s SUPAC-SS guidance||acceptance criteria||positive and negative controls||discriminatory ability||Amphotericin B||Sepigel 305®||Leishmania infantum||cutaneous leishmaniasis||topical treatment||birch bark extract||oleogels||hydrogen bonding||triterpene||rheology||gel strength||eosinophilic esophagitis||budesonide||xanthan gum||guar gum||mucoadhesion||esophagus permeability||rheological characterization||pediatric medicine||compounded preparation||non-ionic emulsifiers||intercellular lipids||confocal Raman spectroscopy (CRS)||polyethylene glycol alkyl ethers||polyethylene glycol sorbitan fatty acid esters||n/a